Younossi, Z. Et Al. 2024. THE IMPACT OF SUPERIMPOSED METABOLICDYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE ( MASLD) ON CLINICAL AND PATIENT- REPORTED OUTCOMES ( PROS) PROFILE OF PATIENTS WITH CHRONIC HEPATITIS B ( CHB) AND C ( CHC). The Liver Meeting , (California, United States Of America).

Younossi, Z., Buti, M., Papatheodoridis, G., YILMAZ, Y., Yu, M., El-Kassas, M., ... Alswat, K.(2024). THE IMPACT OF SUPERIMPOSED METABOLICDYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE ( MASLD) ON CLINICAL AND PATIENT- REPORTED OUTCOMES ( PROS) PROFILE OF PATIENTS WITH CHRONIC HEPATITIS B ( CHB) AND C ( CHC) . The Liver Meeting, California, United States Of America

Younossi, Zobair Et Al. "THE IMPACT OF SUPERIMPOSED METABOLICDYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE ( MASLD) ON CLINICAL AND PATIENT- REPORTED OUTCOMES ( PROS) PROFILE OF PATIENTS WITH CHRONIC HEPATITIS B ( CHB) AND C ( CHC)," The Liver Meeting, California, United States Of America, 2024

Younossi, Zobair Et Al. "THE IMPACT OF SUPERIMPOSED METABOLICDYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE ( MASLD) ON CLINICAL AND PATIENT- REPORTED OUTCOMES ( PROS) PROFILE OF PATIENTS WITH CHRONIC HEPATITIS B ( CHB) AND C ( CHC)." The Liver Meeting , California, United States Of America, 2024

Younossi, Z. Et Al. (2024) . "THE IMPACT OF SUPERIMPOSED METABOLICDYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE ( MASLD) ON CLINICAL AND PATIENT- REPORTED OUTCOMES ( PROS) PROFILE OF PATIENTS WITH CHRONIC HEPATITIS B ( CHB) AND C ( CHC)." The Liver Meeting , California, United States Of America.

@conferencepaper{conferencepaper, author={Zobair Younossi Et Al. }, title={THE IMPACT OF SUPERIMPOSED METABOLICDYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE ( MASLD) ON CLINICAL AND PATIENT- REPORTED OUTCOMES ( PROS) PROFILE OF PATIENTS WITH CHRONIC HEPATITIS B ( CHB) AND C ( CHC)}, congress name={The Liver Meeting}, city={California}, country={United States Of America}, year={2024}}